Matches in Wikidata for { <http://www.wikidata.org/entity/Q66393473> ?p ?o ?g. }
Showing items 1 to 31 of
31
with 100 items per page.
- Q66393473 description "clinical trial" @default.
- Q66393473 description "ensayu clínicu" @default.
- Q66393473 description "klinisch onderzoek" @default.
- Q66393473 description "клінічне випробування" @default.
- Q66393473 name "Brentuximab Vedotin in Chinese Participants With Relapsed/Refractory CD30-Positive Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL)" @default.
- Q66393473 name "Brentuximab Vedotin in Chinese Participants With Relapsed/Refractory CD30-Positive Hodgkin Lymphoma" @default.
- Q66393473 type Item @default.
- Q66393473 label "Brentuximab Vedotin in Chinese Participants With Relapsed/Refractory CD30-Positive Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL)" @default.
- Q66393473 label "Brentuximab Vedotin in Chinese Participants With Relapsed/Refractory CD30-Positive Hodgkin Lymphoma" @default.
- Q66393473 prefLabel "Brentuximab Vedotin in Chinese Participants With Relapsed/Refractory CD30-Positive Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL)" @default.
- Q66393473 prefLabel "Brentuximab Vedotin in Chinese Participants With Relapsed/Refractory CD30-Positive Hodgkin Lymphoma" @default.
- Q66393473 P1050 Q66393473-DB20B8FB-AFA3-4951-B46B-BE906D23ABDE @default.
- Q66393473 P1132 Q66393473-76585292-8C6C-4A9C-9BE8-7607384B8C98 @default.
- Q66393473 P1476 Q66393473-F4641002-098B-49C5-9636-958A8E4F1FE1 @default.
- Q66393473 P2899 Q66393473-0A368CEA-5D05-44DD-A929-360E05BE7B2C @default.
- Q66393473 P3098 Q66393473-EEBB52BF-1EED-4A2F-8D0A-BD42BE6CE893 @default.
- Q66393473 P31 Q66393473-5331832B-F3B0-4FFE-AF25-B6E11C091C52 @default.
- Q66393473 P580 Q66393473-E30F460D-927D-4E90-BD19-633730A890DE @default.
- Q66393473 P582 Q66393473-3A5C877F-5592-4C0E-8410-57ACA56137E8 @default.
- Q66393473 P6099 Q66393473-A33F1FCA-46AF-4A86-B030-662BF9B28E96 @default.
- Q66393473 P8363 Q66393473-F0E296D3-FFB4-4A17-9646-F3594FA71A69 @default.
- Q66393473 P1050 Q208414 @default.
- Q66393473 P1132 "+39" @default.
- Q66393473 P1476 "A Phase 2, Single-Arm, Open-label Study of Brentuximab Vedotin in Chinese Patients With Relapsed/Refractory CD30-Positive Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL)" @default.
- Q66393473 P2899 "+18" @default.
- Q66393473 P3098 "NCT02939014" @default.
- Q66393473 P31 Q30612 @default.
- Q66393473 P580 "2016-11-30T00:00:00Z" @default.
- Q66393473 P582 "2018-08-02T00:00:00Z" @default.
- Q66393473 P6099 Q42824440 @default.
- Q66393473 P8363 Q78089383 @default.